QED Therapeutics, a BridgeBio company
Works in Dermatology · Genetic & rare · Metabolic & endocrine · Oncology
QED Therapeutics, a BridgeBio company is a clinical trial sponsor. It has 5 active clinical trials with 686 planned participants, in Dermatology, Genetic & rare, Metabolic & endocrine and Oncology. Since 2021 it has completed 3 trials and stopped 3 early.
Trial track record · since 2021
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about QED Therapeutics, a BridgeBio company
QED Therapeutics, a BridgeBio company is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 686 planned participants, in Dermatology, Genetic & rare, Metabolic & endocrine, Oncology. Since 2021 it has completed 3 trials and stopped 3 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with QED Therapeutics, a BridgeBio company; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-26.
Approve Suite is not affiliated with QED Therapeutics, a BridgeBio company.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.